{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:22:39Z","timestamp":1787844159031,"version":"build-2784847793"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>Daratumumab (Darzalex; Janssen-Cilag Pty Ltd), an anti-CD38 monoclonal antibody (MoAb), has demonstrated high efficacy in treating relapsed and refractory multiple myeloma (MM). It stands as the pioneering anti-CD38 MoAb approved by the US FDA (2015) and TGA Australia (2017). While targeting CD38 on myeloma cells, daratumumab poses a challenge in pretransfusion testing by inducing panreactivity in indirect antiglobulin tests (IATs) due to CD38 expression on red cells. This study investigates the role of dithiothreitol (DTT) in resolving pretransfusion immunohematology testing in patients treated with daratumumab for MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>Pretransfusion samples from three hematological patients diagnosed with MM and receiving anti-CD38 drugs necessitating red cell transfusion were subjected to immunohematology serological testing. Clinicians provided patient information, including gender, age, transfusion history, and time between anti-CD38 MoAb infusion and sample collection. Tests included ABO\/RhD typing, IAT, both polyspecific and monospecific direct antiglobulin test (DAT), antibody (Ab) screening, Ab identification, eluate preparation, and red cell crossmatch. Control tests were conducted by incubating patient samples at 37\u00b0C for 1 h.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>ABO\/RhD typing remained unaffected, yet all samples exhibited panreactivity in IATs. Two samples showed positive DAT results but negative eluates. Treatment of reagent red blood cells (RBCs) with 0.2 M DTT effectively mitigated interference by anti-CD38 monoclonal antibodies, resulting in compatible red cell crossmatches. Notably, incubation of patient samples at 37\u00b0C for 1 h yielded identical results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Pretreatment of erythrocytes with DTT deactivated the CD38 antigen, eliminating reactivity with patient serum treated with daratumumab. DTT treatment of reagent RBCs emerges as an efficient and accessible strategy to counteract interference from anti-CD38 drugs in pretransfusion tests.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ajts.ajts_146_23","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T06:29:53Z","timestamp":1724826593000},"page":"258-262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Role of dithiothreitol in the resolution of pretransfusion immunohematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma"],"prefix":"10.4103","volume":"20","author":[{"given":"Anshika","family":"Yadav","sequence":"first","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Immunohematology and Transfusion Medicine, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gajendra Nath","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pathology and Transfusion Medicine, Santokba Durlabhji Memorial Hospital, Jaipur, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"R1-20260529","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"R2-20260529","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20260529","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","article-title":"Daratumumab:First global approval","volume":"76","author":"McKeage","year":"2016","journal-title":"Drugs"},{"key":"R5-20260529","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.14694\/EdBook_AM.2015.35.e504","article-title":"Multiple myeloma:From front-line to relapsed therapies","volume":"35","author":"Moreau","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R6-20260529","first-page":"73","article-title":"Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma data from a dose escalation phase I\/II study","volume":"120","author":"Plsener","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"Suppl. 15","key":"R7-20260529","article-title":"Phase I\/II dose-escalation study of daratumumab in patients with relapsed refractory multiple myeloma","volume":"31","author":"Lokhorst","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"key":"R8-20260529","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20260529","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20260529","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"R11-20260529","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1006\/bbrc.1993.2416","article-title":"Asingle protein immunologically identified as CD38 displays NAD +glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes","volume":"196","author":"Zocchi","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"R12-20260529","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"},{"key":"R13-20260529","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"key":"R14-20260529","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s40265-016-0573-4","article-title":"Practical considerations for the use of daratumumab, a novel CD38 monoclonal antibody, in Myeloma","volume":"76","author":"Moreau","year":"2016","journal-title":"Drugs"},{"key":"R15-20260529","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/trf.14144","article-title":"How do I work up pretransfusion samples containing anti-CD38?","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"R16-20260529","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/trf.14021","article-title":"Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"R17-20260529","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1111\/trf.13267","article-title":"Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma","volume":"55","author":"Hannon","year":"2015","journal-title":"Transfusion"},{"key":"R19-20260529","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/trf.13474","article-title":"Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing","volume":"56","author":"De Vooght","year":"2016","journal-title":"Transfusion"},{"key":"R22-20260529","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/trf.13174","article-title":"An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab","volume":"55","author":"Schmidt","year":"2015","journal-title":"Transfusion"},{"key":"R24-20260529","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"R25-20260529","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"R26-20260529","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century:A population-based study","volume":"28","author":"Turesson","year":"2010","journal-title":"J Clin Oncol"},{"key":"R27-20260529","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS):An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"R30-20260529","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V128.22.489.489","article-title":"Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone for relapsed or refractory multiple myeloma among patients with 1 to 3 prior lines of therapy based on previous treatment exposure:Updated analysis of POLLUX","volume":"128","author":"Moreau","year":"2016","journal-title":"Blood"}],"container-title":["Asian Journal of Transfusion Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_146_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:12:15Z","timestamp":1787843535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_146_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ajts.ajts_146_23","relation":{},"ISSN":["0973-6247","1998-3565"],"issn-type":[{"value":"0973-6247","type":"print"},{"value":"1998-3565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"2023-07-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}